Clinical Study

Biomarkers Of Disease Progression In Progressive Supranuclear Palsy

Posted Date: Mar 13, 2023

  • Investigator: Alberto Espay
  • Specialties: Movement Disorders, Neurology
  • Type of Study: Observational/Survey

Progressive supranuclear palsy (PSP) is an atypical parkinsonian disorder that manifests with several clinical phenotypes and different related disease progressions (Respondek et al., 2014). There is increasing interest in identifying biomarkers of disease progression in PSP patients (Boxer et al., 2017). This study will examine whether levels of biomarkers (Aß42, p-tau and t-tau in CSF, selected subpopulations of PBMCs, and transcriptomics and proteomics) are associated with "benign" versus "malignant" disease progression in PSP patients. DNA analysis and MRI data will also be analyzed when available. We will enroll up to 40 patients, perform clinical assessments and collect blood yearly for 3 years and, optionally, CSF twice one year apart.


Subjects 18 Years Old Or Older With Diagnosis Of Probably Or Possible Psp Based On Current Clinical Diagnostic Criteria (Hoglinger Et Al., 2017) And Either A Disease Duration Of 10 Years Of More Since Symptoms Onset ("Benign" Phenotype) Or Need Of Wheelchair Within 4 Years Of Symptoms Onset ("Malignant" Phenotype)


Psp, Progressive Supranuclear Palsy, Ab42

For More Information:

Kevin Duque

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.